LTIP888A - Polyethylene glycol -interferon conjugates - Google Patents

Polyethylene glycol -interferon conjugates

Info

Publication number
LTIP888A
LTIP888A LTIP888A LTIP888A LTIP888A LT IP888 A LTIP888 A LT IP888A LT IP888 A LTIP888 A LT IP888A LT IP888 A LTIP888 A LT IP888A LT IP888 A LTIP888 A LT IP888A
Authority
LT
Lithuania
Prior art keywords
polyethylene glycol
interferon conjugates
conjugates
interferon
production
Prior art date
Application number
LTIP888A
Other languages
Lithuanian (lt)
Inventor
Robert Karasiewicz
Carlo Nalin
Perry Rosen
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of LTIP888A publication Critical patent/LTIP888A/en
Publication of LT3174B publication Critical patent/LT3174B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Šiame išradime aprašomi fiziologiškai aktyvūs, tirpūs vandenyje polietilenglikolio konjungtai su interferonu ir nauji polietilenglikolio junginiai, kurie gali būti panaudoti konjugatų gamybai.The present invention describes physiologically active, water-soluble polyethylene glycol conjugated to interferon and novel polyethylene glycol compounds that may be used in the production of conjugates.

LTIP888A 1992-08-26 1993-08-25 Polyethylene glycol -interferon conjugates LT3174B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/935,770 US5382657A (en) 1992-08-26 1992-08-26 Peg-interferon conjugates

Publications (2)

Publication Number Publication Date
LTIP888A true LTIP888A (en) 1994-08-25
LT3174B LT3174B (en) 1995-02-27

Family

ID=25467637

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP888A LT3174B (en) 1992-08-26 1993-08-25 Polyethylene glycol -interferon conjugates

Country Status (37)

Country Link
US (1) US5382657A (en)
EP (1) EP0593868B1 (en)
JP (1) JP2859105B2 (en)
KR (1) KR100295520B1 (en)
CN (3) CN1183112C (en)
AT (1) ATE165102T1 (en)
AU (1) AU668742B2 (en)
BG (1) BG98067A (en)
BR (1) BR9303469A (en)
CA (1) CA2103829C (en)
CZ (1) CZ169393A3 (en)
DE (1) DE69317979T2 (en)
DK (1) DK0593868T3 (en)
EE (1) EE9400151A (en)
ES (1) ES2116376T3 (en)
FI (1) FI109765B (en)
HR (1) HRP931094A2 (en)
HU (1) HUT67013A (en)
IL (1) IL106750A0 (en)
IS (1) IS4067A (en)
LT (1) LT3174B (en)
LV (1) LV10907B (en)
MW (1) MW7693A1 (en)
MX (1) MX9305146A (en)
MY (1) MY131445A (en)
NO (1) NO933028D0 (en)
NZ (2) NZ264872A (en)
OA (1) OA09850A (en)
PH (1) PH30460A (en)
PL (1) PL300194A1 (en)
RO (1) RO112730B1 (en)
SI (1) SI9300423A (en)
SK (1) SK89893A3 (en)
UY (1) UY23635A1 (en)
YU (1) YU56693A (en)
ZA (1) ZA936098B (en)
ZW (1) ZW11193A1 (en)

Families Citing this family (291)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
ES2238070T3 (en) 1989-04-21 2005-08-16 Amgen Inc. TNF RECEPTOR, TNF BINDING PROTEIN AND CODANT DNA FOR THESE.
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
KR960705579A (en) * 1993-11-10 1996-11-08 에릭에스. 딕커 Improved interferon polymer conjugates
PT726778E (en) * 1994-02-08 2001-12-28 Amgen Inc ORAL ADMINISTRATION SYSTEM OF CHEMICALLY MODIFIED G-CSF PROTEINS
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
DE4435087A1 (en) * 1994-09-30 1996-04-04 Deutsches Krebsforsch Conjugate for the treatment of infectious, autoimmune and skin diseases
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
DE19514087A1 (en) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Conjugate of an active ingredient, a polyether and possibly a native protein that is not considered foreign to the body
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
JP2000507917A (en) 1995-11-02 2000-06-27 シェーリング コーポレイション Continuous low-dose cytokine infusion therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
WO2000042175A1 (en) 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
DE69838552T2 (en) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
CN1276730A (en) * 1997-09-18 2000-12-13 霍夫曼-拉罗奇有限公司 Use of IFN-alpha and amantadine for treatment of chronic hepatitis C
EP1037649B1 (en) 1997-12-17 2009-09-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
FR2774687B1 (en) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med LIPOPEPTIDES CONTAINING A FRAGMENT OF THE INTERFERON GAMMA, AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
CZ302005B6 (en) * 1998-03-26 2010-09-01 Schering Corporation Aqueous agent of PEG-interferon alpha conjugate, lyophilizate thereof and product containing it
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
ES2224649T3 (en) * 1998-04-28 2005-03-01 Applied Research Systems Ars Holding N.V. CONJUGATES OF POLIOL-IFN-BETA.
AU766597B2 (en) 1998-05-15 2003-10-16 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection
WO1999061055A1 (en) * 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
ITMI981148A1 (en) * 1998-05-22 1999-11-22 Therapicon Srl USE OF MODIFIED LYSOZYME C TO PREPARE MEDICINE COMPOSITIONS FOR THE TREATMENT OF SOME SERIOUS DISEASES
NZ508249A (en) * 1998-06-08 2003-02-28 F Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C
US20030143662A1 (en) * 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
JP2002518354A (en) * 1998-06-16 2002-06-25 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ Glycosulfate peptides, their synthesis and use
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
EP2599503B1 (en) 1998-10-16 2017-05-17 Biogen MA Inc. Polymer conjugates of interferon beta-1A and uses thereof
DK1121382T3 (en) * 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta fusion proteins and their applications
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CN1376164A (en) * 1999-01-29 2002-10-23 霍夫曼-拉罗奇有限公司 GCSF conjugates
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
TWI292320B (en) 1999-04-08 2008-01-11 Schering Corp Melanoma therapy
PE20010288A1 (en) 1999-07-02 2001-03-07 Hoffmann La Roche ERYTHROPOYETIN DERIVATIVES
ES2364086T3 (en) 1999-07-07 2011-08-24 Zymogenetics, Inc. HUMAN CYTOKIN RECEPTOR.
WO2001005819A1 (en) * 1999-07-15 2001-01-25 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) * 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
CA2387205A1 (en) 1999-10-12 2001-04-19 Santen Pharmaceutical Co., Ltd. Interferon complex and pharmaceutical use thereof
KR20020065517A (en) * 1999-11-12 2002-08-13 맥시겐 홀딩스 리미티드 Interferon gamma conjugates
US7230081B1 (en) 1999-11-12 2007-06-12 Maxygen Holdings, Ltd. Interferon gamma conjugates
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
WO2001035978A1 (en) 1999-11-19 2001-05-25 The Board Of Trustees Of The Leland Stanford Junior University Targeted bifunctional molecules and therapies based thereon
CA2393369A1 (en) 1999-12-03 2001-06-07 Zymogenetics, Inc. Human cytokine receptor
HUP0203751A3 (en) 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
CA2397793A1 (en) * 2000-01-24 2001-07-26 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
DE60138364D1 (en) 2000-02-11 2009-05-28 Bayer Healthcare Llc CLEANING FACTOR VII OR VIIA CONJUGATE
KR100353392B1 (en) * 2000-03-13 2002-09-18 선바이오(주) Method of Preparing the PEG-Protein Composition Having Enhanced Biological Activity
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
EP1333036B1 (en) * 2000-10-16 2009-01-21 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
ES2329012T3 (en) 2000-11-07 2009-11-20 Zymogenetics, Inc. RECEIVER OF THE HUMAN TUMOR NECROSIS FACTOR.
MXPA03007392A (en) * 2001-02-20 2003-12-04 Enzon Inc Terminally-branched polymeric linkers and polymeric conjugates containing the same.
EP2301971A1 (en) 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI
MXPA03007619A (en) 2001-02-27 2003-12-04 Maxygen Aps New interferon beta-like molecules.
JP2004532624A (en) 2001-03-02 2004-10-28 ザイモジェネティクス，インコーポレイティド Mouse cytokine receptor
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
WO2002083166A1 (en) * 2001-04-10 2002-10-24 Santen Pharmaceutical Co., Ltd. Interferon-polymer complexes and medicinal use thereof
PL403488A1 (en) 2001-05-24 2013-07-08 Zymogenetics, Inc. Use of a fusion protein TACI-immunoglobulin fusion protein, a nucleic acid molecule encoding a fusion protein, the pharmaceutical composition and a method for producing the fusion protein TACI-immunoglobulin
JP4142569B2 (en) * 2001-06-22 2008-09-03 協和醗酵工業株式会社 Ointment
MD2053C2 (en) * 2001-07-10 2003-07-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Remedy with interferon inducing action
EP1419191B1 (en) 2001-08-22 2007-10-17 Bioartificial Gel Technologies Inc. Process for the preparation of activated polyethylene glycols
US20050095224A1 (en) * 2001-12-07 2005-05-05 Ramachandran Radhakrishnan Compositions and method for treating hepatitis virus infection
KR100888371B1 (en) 2002-01-17 2009-03-13 동아제약주식회사 Antiviral agent including branched polymer derivative and interferon conjugate
SK3102004A3 (en) * 2002-01-18 2005-01-03 Biogen Idec MA Inc. Polyalkylene polymer compounds and uses thereof
EP1496076B1 (en) * 2002-03-13 2007-07-25 Beijing Jiankai Technology Co., Ltd. Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
AU2003223482A1 (en) * 2002-04-11 2003-10-27 Zymogenetics, Inc. Use of interleukin-24 to treat ovarian cancer
CN101676728A (en) 2002-04-19 2010-03-24 津莫吉尼蒂克斯公司 cytokine receptor
KR101186140B1 (en) 2002-06-21 2012-09-27 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Pegylated factor vii glycoforms
AU2003239774A1 (en) * 2002-07-03 2004-01-23 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
JP4451308B2 (en) 2002-07-24 2010-04-14 エフ．ホフマン−ラ ロシュ アーゲー Polyalkylene glycolic acid additive
CN1691956A (en) * 2002-09-05 2005-11-02 通用医疗公司 Asialo-interferons and the treatment of liver cancer
AU2003270341A1 (en) * 2002-09-05 2004-03-29 The General Hospital Corporation Modified asialo-interferons and uses thereof
JP4237703B2 (en) * 2002-09-27 2009-03-11 エフ．ホフマン−ラ ロシュ アーゲー Insulin-like growth factor binding protein-4 and poly (ethylene glycol) conjugate
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
MXPA05006944A (en) * 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta.
JP2006519170A (en) * 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones, and their antagonists with conserved receptor binding activity
EP1581260B1 (en) * 2002-12-31 2014-09-17 Nektar Therapeutics Polymeric reagents comprising a ketone or a related functional group
EP1597299A2 (en) * 2003-02-19 2005-11-23 Pharmacia Corporation Carbonate esters of polyethylene glycol activated by means of oxalate esters
CA2516552A1 (en) * 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
WO2004078127A2 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Continuous delivery methods for treating hepatitis virus infection
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
EP2251353B1 (en) 2003-08-07 2013-03-06 ZymoGenetics, Inc. Homogeneous preparations of IL-29
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
EP1673387B1 (en) 2003-10-10 2010-09-15 Novo Nordisk A/S Il-21 derivatives
TW201245229A (en) 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US20050089952A1 (en) * 2003-10-22 2005-04-28 Akzo Nobel N.V. Apparatuses and processes for increasing protein PEGylation reaction yields
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
WO2005062949A2 (en) * 2003-12-23 2005-07-14 Intermune, Inc. Method for treating hepatitis virus infection
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
NZ548255A (en) * 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
RU2311930C2 (en) * 2004-04-30 2007-12-10 Закрытое акционерное общество "ВЕРОФАРМ" Pagylated interferon against viral infection
AU2005245918A1 (en) * 2004-05-19 2005-12-01 F. Hoffmann-La Roche Ag Interferon-alpha polypeptides and conjugates
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
KR20070034512A (en) * 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 New Antigen-Binding Polypeptides and Uses thereof
AU2009212311B8 (en) 2004-07-21 2013-05-30 Ambrx, Inc. Modified leptin polypeptides and their uses
EP1771573A4 (en) * 2004-07-21 2009-02-18 Ambrx Inc Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EP1793845A2 (en) 2004-07-29 2007-06-13 ZymoGenetics, Inc. Use of il-28 and il-29 to treat cancer
DE602005022895D1 (en) 2004-08-12 2010-09-23 Schering Corp STABLE PEGYLATED INTERFERON FORMULATION
US20060204512A1 (en) 2004-09-23 2006-09-14 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
NZ555386A (en) * 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
WO2006073846A2 (en) * 2004-12-22 2006-07-13 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
ATE541934T1 (en) * 2004-12-22 2012-02-15 Ambrx Inc AMINOACYL TRNA SYNTHETASE COMPOSITIONS AND USES THEREOF
JP2008525473A (en) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド Modified human growth hormone
EP1856156A2 (en) 2005-02-08 2007-11-21 ZymoGenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
EP2399932B1 (en) 2005-05-12 2016-11-16 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
AU2006299901A1 (en) * 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
MX2007015058A (en) * 2005-06-03 2008-01-28 Ambrx Inc Improved human interferon molecules and their uses.
EP1893240A2 (en) * 2005-06-13 2008-03-05 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
BRPI0613142A2 (en) 2005-06-17 2010-12-21 Novartis Ag use of sangliferin in hcv
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
KR20080037656A (en) * 2005-06-20 2008-04-30 펩젠 코포레이션 Low-toxic long-circulating human interferon-alpha analogs and chimeras of interferon tau
EP2476428B1 (en) * 2005-06-29 2013-08-21 Yeda Research and Development Co. Ltd. Recombinant interferon alpha 2 (IFN alpha 2) mutants
NZ565059A (en) 2005-07-25 2011-08-26 Intermune Inc Novel macrocyclic inhibitors of hepatitus C virus replication
KR101285904B1 (en) * 2005-08-18 2013-07-15 암브룩스, 인코포레이티드 COMPOSITIONS OF tRNA AND USES THEREOF
CA2621623A1 (en) 2005-09-28 2007-04-05 Zymogenetics, Inc. Il-17a and il-17f antagonists and methods of using the same
BRPI0617274A2 (en) 2005-10-11 2011-07-19 Intermune Inc compounds and methods for inhibiting hepatitis c viral replication
CA2622210A1 (en) * 2005-10-21 2007-04-26 Avigenics, Inc. Glycolated and glycosylated poultry derived therapeutic proteins
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
CA2625540C (en) * 2005-11-08 2017-03-21 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
CN101454461A (en) * 2005-11-16 2009-06-10 Ambrx公司 Methods and compositions comprising unnatural amino acids
NZ568578A (en) * 2005-12-14 2011-10-28 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
KR101418607B1 (en) 2006-01-12 2014-07-14 호쿠산 가부시키가이샤 Oral composition containing interferon-α
CN100475270C (en) 2006-01-20 2009-04-08 清华大学 Medicine for treating tumor and application thereof
CN101002945B (en) 2006-01-20 2012-09-05 清华大学 Novel complex used for treating tumor
EP2007789B1 (en) 2006-04-11 2015-05-20 Novartis AG Spirocyclic HCV/HIV inhibitors and their uses
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2395099A3 (en) * 2006-05-02 2012-05-16 Allozyne, Inc. Amino acid substituted molecules
RU2008145084A (en) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) ANALOGUES OF FACTOR IX HAVING A LONG-TERM HALF-TIME IN VIVO
US7985734B2 (en) 2006-06-01 2011-07-26 Yun Cheng Peptides for preventing or treating liver damage
CN1911447B (en) * 2006-06-30 2010-05-12 复旦大学 Transferrin-polyethylene glycol-drug molecule complex and its application for preparing medicine
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP2054076A2 (en) * 2006-08-21 2009-05-06 United Therapeutics Corporation Combination therapy for treatment of viral infections
CN106008699A (en) * 2006-09-08 2016-10-12 Ambrx公司 Modified human plasma polypeptide or Fc scaffolds and their uses
AU2007292892B9 (en) * 2006-09-08 2013-02-28 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
AU2007292893B2 (en) * 2006-09-08 2012-03-01 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
CN101219219B (en) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 Complex containing vascellum chalone or fragment, preparation method and application thereof
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CN101675071B (en) * 2007-05-02 2014-06-18 Ambrx公司 Modified interferon beta polypeptides and uses thereof
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
KR101483814B1 (en) 2007-09-04 2015-01-16 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 Interferon alpha 2a modified by polyethylene glycol, its synthesis process and application
US8597635B2 (en) 2007-09-04 2013-12-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha-2B modified by polyethylene glycol and methods of preparation thereof
EA201000343A1 (en) 2007-10-04 2011-10-31 Займодженетикс, Инк. MEMBER OF THE FAMILY B7, zB7H6 AND RELATED COMPOSITIONS AND METHODS
MX2010004327A (en) 2007-10-22 2010-05-13 Schering Corp Fully human anti-vegf antibodies and methods of using.
ES2632504T3 (en) 2007-11-20 2017-09-13 Ambrx, Inc. Modified insulin polypeptides and their uses
WO2009071696A2 (en) 2007-12-07 2009-06-11 Zymogenetics, Inc. Humanized antibody molecules specific for il-31
JP5458416B2 (en) 2008-04-03 2014-04-02 バイオスティード ジーン エクスプレッション テック． カンパニー リミテッド Double-chain polyethylene glycolated growth hormone, process for its production and use thereof
CN102099373A (en) 2008-05-22 2011-06-15 百时美施贵宝公司 Multivalent fibronectin based scaffold domain proteins
JP2011526154A (en) 2008-06-27 2011-10-06 ザイモジェネティクス， インコーポレイテッド Soluble hybrid Fcγ receptor and related methods
CN106928339A (en) 2008-07-23 2017-07-07 Ambrx 公司 Modified ox G CSF polypeptides and its purposes
CA2737026C (en) 2008-09-26 2019-12-24 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
PT2337846T (en) 2008-09-26 2018-04-05 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
WO2010039801A2 (en) 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
CN102448458B (en) 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 Methods and compositions for treating viral infections of the Flaviviridae family
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
AU2010256410B2 (en) 2009-06-04 2016-10-20 Massachusetts Institute Of Technology Methods for identification of sites for IgG conjugation
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
JP2013508425A (en) 2009-10-30 2013-03-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dosage treatment plan for HCV combination therapy including BI201335, interferon alfa and ribavirin
EP2516455A4 (en) 2009-12-21 2013-05-22 Ambrx Inc MODIFIED PORCINE GROWTH HORMONE POLYPEPTIDES AND USES THEREOF
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
EP2576615B1 (en) 2010-05-26 2016-03-30 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
CN102711871A (en) 2010-06-16 2012-10-03 麦德托尼克公司 Damping systems for stabilizing medications in drug delivery devices
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
JP2013529627A (en) 2010-06-24 2013-07-22 パンメド リミテッド Treatment of hepatitis C virus-related disease using hydroxychloroquine or a combination of hydroxychloroquine and an antiviral agent
EP2595632A1 (en) 2010-07-23 2013-05-29 DemeRx, Inc. Noribogaine compositions
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP2605789B1 (en) 2010-08-17 2019-06-05 Ambrx, Inc. Modified relaxin polypeptides and their uses
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
KR20140035305A (en) 2010-10-05 2014-03-21 노파르티스 아게 New treatments of hepatitis c virus infection
CA2811799A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
BR112013013166A2 (en) 2010-11-30 2016-09-06 Novartis Ag hepatitis c virus infection treatments
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
EP2691094A1 (en) 2011-03-31 2014-02-05 Novartis AG Alisporivir to treat hepatitis c virus infection
DK2694087T3 (en) 2011-04-01 2015-04-13 Novartis Ag The treatment of infection with Hepatitis B virus alone or in combination with hepatitis delta virus, and in connection with liver diseases
US20150104415A1 (en) 2011-04-13 2015-04-16 Debiopharm International Sa Treatments of Hepatitis C virus infection
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
EP2709648A4 (en) 2011-05-19 2015-04-08 Geysen Hendrik M Compounds that bind to the erythropoietin receptor
WO2013004607A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
US20140314713A1 (en) 2011-07-20 2014-10-23 Universite Paris Diderot - Paris Vii Methods for determining treatment response in patients infected with hcv genotype 4
EP2748328A4 (en) * 2011-08-25 2015-03-04 Nanogen Pharmaceutical Biotechnology Peg-interferon lambda 1 conjugates
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
KR20140070565A (en) 2011-09-27 2014-06-10 노파르티스 아게 Alisporivr for treatment of hepatis c virus infection
WO2013067029A2 (en) 2011-10-31 2013-05-10 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US9364484B2 (en) 2011-12-06 2016-06-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating viral diseases
EP2788003A4 (en) 2011-12-09 2015-05-27 Demerx Inc Phosphate esters of noribogaine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
CN104411332B (en) 2012-03-30 2018-11-23 索伦托治疗有限公司 Human antibody in conjunction with VEGFR2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2013174988A1 (en) 2012-05-24 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
ES2718478T3 (en) 2012-06-08 2019-07-02 Sutro Biopharma Inc Antibodies comprising non-natural amino acid residues of specific location, methods for their preparation and methods for their use
CA2877573A1 (en) 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
HK1208236A1 (en) 2012-06-22 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
AU2013308494B2 (en) 2012-08-31 2018-03-01 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
WO2014098877A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
CN111423511B (en) 2013-05-31 2024-02-23 索伦托药业有限公司 Antigen binding proteins that bind to PD-1
ES2865473T3 (en) 2013-07-10 2021-10-15 Sutro Biopharma Inc Antibodies Comprising Multiple Site-Specific Unnatural Amino Acid Residues, Methods for Their Preparation, and Methods of Use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
LT3137078T (en) 2014-05-01 2019-06-25 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2015195673A2 (en) 2014-06-18 2015-12-23 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
EP3180018B1 (en) 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
WO2016028523A2 (en) 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr3
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
KR102854572B1 (en) 2014-10-24 2025-09-02 브리스톨-마이어스 스큅 컴퍼니 Modified fgf-21 polypeptides and uses thereof
ES2966888T3 (en) 2014-11-06 2024-04-24 Pharmaessentia Corp Dosing Regimen for Pegylated Interferon
US20180066229A1 (en) * 2015-03-17 2018-03-08 Shinshu University Method for preparing dendritic cells via non-adhesive culture using ifn
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
WO2017076791A1 (en) 2015-11-03 2017-05-11 F. Hoffmann-La Roche Ag Combination therapy of an hbv capsid assembly inhibitor and an interferon
JP7187315B2 (en) 2015-11-04 2022-12-12 アイガー・バイオファーマシューティカルズ・インコーポレイテッド Treatment of hepatitis delta virus infection
BR112018015480A2 (en) 2016-01-29 2019-05-21 Sorrento Therapeutics, Inc. pd-l1-binding antigen binding proteins
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
US10603358B2 (en) 2017-01-10 2020-03-31 Nodus Therapeutics Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
US20190374611A1 (en) 2017-01-18 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
BR112019016139A2 (en) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company modified relaxin polypeptide comprising a pharmacokinetic enhancer and uses thereof
WO2019020593A1 (en) 2017-07-25 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
US11446365B2 (en) 2017-08-09 2022-09-20 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
WO2020056066A1 (en) 2018-09-11 2020-03-19 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
CA3113618A1 (en) 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
US11235032B2 (en) 2019-01-23 2022-02-01 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
TW202146011A (en) 2020-03-05 2021-12-16 美商詹森藥物公司 Combination therapy for treating hepatitis b virus infection
CN120682337A (en) 2020-03-11 2025-09-23 北京泰德制药股份有限公司 Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
EP3912627B1 (en) 2020-05-20 2022-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of coronavirus infections
TW202207950A (en) 2020-06-22 2022-03-01 美商詹森藥物公司 Compositions and methods for treatment of hepatitis d virus infection
TW202227449A (en) 2020-08-20 2022-07-16 美商Ａｍｂｒｘ 公司 Antibody-tlr agonist conjugates, methods, and uses thereof
WO2022043496A2 (en) 2020-08-28 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mait cells as biomarkers and biotargets in covid-19
WO2022079205A1 (en) 2020-10-15 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ifn-alpha polypeptides for the treatment of coronavirus infections
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
MX2023011480A (en) 2021-04-03 2023-12-06 Ambrx Inc ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES OF THESE.
WO2024164213A1 (en) 2023-02-09 2024-08-15 谢彦晖 Treatment of atopic dermatitis with polyethylene glycol-modified interleukin 2, glucocorticoid and hyaluronic acid
WO2025006676A2 (en) 2023-06-27 2025-01-02 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2651657A (en) * 1949-05-21 1953-09-08 Standard Oil Dev Co Synthetic lubricating oil
SE337223B (en) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (en) * 1967-12-20 1972-03-06 Pharmacia Ab
DK132327A (en) * 1968-07-16
US3632828A (en) * 1968-12-16 1972-01-04 Dow Chemical Co Polyethylene glycol monomethyl ether carbonates
BE758425A (en) * 1969-12-02 1971-04-16 Baxter Laboratories Inc STREPTOKINASE CHEMICALLY LINKED TO A CARBOHYDRATE MATRIX (
DE2247163A1 (en) * 1972-09-26 1974-03-28 Merck Patent Gmbh CARRIER MATRIX FOR FIXING BIOLOGICALLY ACTIVE SUBSTANCES AND THE PROCESS FOR THEIR PRODUCTION
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
US4094744A (en) * 1976-11-18 1978-06-13 W. R. Grace & Co. Water-dispersible protein/polyurethane reaction product
EP0000938B1 (en) * 1977-08-22 1984-10-17 National Research Development Corporation Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
JPS55110105A (en) * 1979-02-19 1980-08-25 Japan Atom Energy Res Inst Preparation of polymer composition containing physiologically active material
JPS6023084B2 (en) * 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
US4486344A (en) * 1983-03-28 1984-12-04 Miles Laboratories, Inc. Urea-linked immunogens, antibodies, and preparative method
JPS6098988A (en) * 1983-11-01 1985-06-01 Chemo Sero Therapeut Res Inst Purification of lpf-ha
JPS60127952A (en) 1983-12-14 1985-07-08 Fanuc Ltd Regional work
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2524586B2 (en) * 1985-06-26 1996-08-14 シタス コーポレイション Solubilization of proteins for pharmaceutical compositions utilizing polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US4818769A (en) * 1985-09-20 1989-04-04 Cetus Corporation Method of controlling stress-related disease in livestock by administration of human IL-2
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
CA1308377C (en) * 1987-08-21 1992-10-06 Henry Berger, Jr. Complex of polyethyleneglycol and tissue plasminogen activator
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5199360A (en) 1988-09-27 1993-04-06 Sirkka Koistinen Table constructions
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
JPH04502011A (en) * 1988-11-23 1992-04-09 ジェネンテク，インコーポレイテッド polypeptide derivative
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
EP0893439B1 (en) * 1989-04-19 2005-07-27 Enzon, Inc. A process for forming a modified polypeptide comprising a polypeptide and a polyalkylene oxide
DK0400472T3 (en) * 1989-05-27 1996-05-13 Sumitomo Pharma Process for the preparation of polyethylene glycol derivatives and modified protein
JP2978187B2 (en) * 1989-11-02 1999-11-15 日本ケミカルリサーチ株式会社 Method for producing modified superoxide dismutase
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
ES2084149T3 (en) * 1989-12-01 1996-05-01 Basf Ag CONJUGATES OF HIRUDINPOLIALQUILENGLICOL.
JPH04202293A (en) * 1990-11-29 1992-07-23 Tonen Corp hydraulic oil
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation

Also Published As

Publication number Publication date
CA2103829A1 (en) 1994-02-27
CN1183112C (en) 2005-01-05
HUT67013A (en) 1995-01-30
BG98067A (en) 1994-12-02
EE9400151A (en) 1996-02-15
YU56693A (en) 1997-01-08
NZ248452A (en) 1995-12-21
DE69317979T2 (en) 1998-08-20
US5382657A (en) 1995-01-17
MY131445A (en) 2007-08-30
CA2103829C (en) 2003-04-08
BR9303469A (en) 1994-03-22
EP0593868A1 (en) 1994-04-27
PL300194A1 (en) 1994-04-05
EP0593868B1 (en) 1998-04-15
RO112730B1 (en) 1997-12-30
IL106750A0 (en) 1993-12-08
NO933028D0 (en) 1993-08-25
JP2859105B2 (en) 1999-02-17
IS4067A (en) 1994-02-27
SK89893A3 (en) 1994-04-06
ZW11193A1 (en) 1994-03-23
FI933740A0 (en) 1993-08-25
NZ264872A (en) 1996-01-26
DE69317979D1 (en) 1998-05-20
CZ169393A3 (en) 1994-04-13
CN1211578A (en) 1999-03-24
PH30460A (en) 1997-05-28
HU9302366D0 (en) 1993-11-29
AU4478093A (en) 1994-03-03
MX9305146A (en) 1994-03-31
OA09850A (en) 1994-08-15
MW7693A1 (en) 1994-06-08
ZA936098B (en) 1994-03-01
ATE165102T1 (en) 1998-05-15
LV10907A (en) 1995-12-20
FI109765B (en) 2002-10-15
LV10907B (en) 1996-04-20
KR100295520B1 (en) 2001-09-17
CN1039015C (en) 1998-07-08
HRP931094A2 (en) 1997-06-30
DK0593868T3 (en) 1999-02-08
CN1155618C (en) 2004-06-30
CN1088936A (en) 1994-07-06
FI933740L (en) 1994-02-27
UY23635A1 (en) 1994-03-01
ES2116376T3 (en) 1998-07-16
LT3174B (en) 1995-02-27
AU668742B2 (en) 1996-05-16
JPH06192300A (en) 1994-07-12
KR940003969A (en) 1994-03-14
SI9300423A (en) 1994-03-31
CN1173500A (en) 1998-02-18

Similar Documents

Publication Publication Date Title
LTIP888A (en) Polyethylene glycol -interferon conjugates
FI964681A0 (en) Lactobacillus strains of human origin, their compositions and their uses
ATE244015T1 (en) FORMULATIONS FOR FACTOR IX
ES2110386T3 (en) INTERFERON CONJUGATES.
ATE172477T1 (en) OLIGOMERS, THEIR USES AND FORMULATIONS
YU15499A (en) Olanzapine dihydrate d
ATE203519T1 (en) QUINOLINE DERIVATIVES AS ANTIMALARIATIC AGENTS
MY133125A (en) Novel dihydroxyhexanoic acid derivatives
NO964238L (en) Halofantrine-free base for the treatment of malaria and mixtures
DK1092431T3 (en) Lasofoxifene preparations
HUP9902415A2 (en) Solid instant-release forms of administration and process for producing the same
AU109615S (en) Ground engaging element
BG100248A (en) SQUALENSENTEZA INHIBITORS
TR200200599T2 (en) Human insulin monomeric analogues.
FR2652742B1 (en) COSMETIC AND DERMO-PHARMACEUTICAL ANALLERGIC COMPOSITIONS.
IT9048066A0 (en) 2- 6, 7-SUSTITUTED AMINOTETRALINES ACTIVE AS IMMUNOMODULANTS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
NL194918B (en) SDK peptide, and therapeutic compositions containing it.
IT1264546B1 (en) PHARMACEUTICAL COMPOSITION WITH ANTI-ACID ACTIVITY IN THE FORM OF A SUCRALFATE GEL-BASED SUSPENSION
IT1254452B (en) N-OXIDES AND N, N'-DIOXIDES OF 3- (PIPERAZIN-1-IL) -PROPAN-1,2-DIOLS
RU93050376A (en) POLYETHYLENE GLYCOL INTERFERON COMPOUNDS
AU132015S (en) Pants
AU103662S (en) Trousers
AU114105S (en) Washbasin
AU124219S (en) Edging
SV1990000045A (en) PREPARATION OF CYCLLOALCAN [B] DEHYDROINDOL E-INOSULFONAMIDES SUBSTITUTED, REF. LE A 27 157-SV.

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 19970825